| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445374 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
Based on pharmacokinetics, acceptable safety and encouraging antitumour activity, aflibercept 4Â mg/kg was selected as the RPTD with irinotecan and LV5FU2 every 2Â weeks.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eric Van Cutsem, David Khayat, Chris Verslype, Bertrand Billemont, Sabine Tejpar, Jean-Baptiste Meric, Karen Soussan-Lazard, Sylvie Assadourian, Sylvaine Cartot-Cotton, Olivier Rixe,